文/梧桐晓编 2026年3月2日,公司及相关当事人收到中国证监会浙江监管局出具的《行 政处罚事先告知书》（浙处罚字【2026】1 号）,现将相关情况公告如下: 二、《行政处罚事先告知书》的主要内容 浙江向日葵大健康科技股份有限公司、吴少钦先生、李岚女士: 浙江向日葵大健康科技股份有限公司(以下简称向日葵或公司)涉嫌信息披 露违法违规一案,已由我局调查完毕,我局依法拟对你们作出行政处罚。现将我 局拟对你们作出行政处罚所根据的违法事实、理由、依据及你们享有的相关权利 予以告知。 经查明,当事人涉嫌违法的事实如下: 2025年9月22日,向日葵披露《发行股份及支付现金购买资产并募集配套 资金暨关联交易预案》(以下简称《预案》),称公司拟通过发行股份及支付现 金的方式购买漳州兮璞材料科技有限公司(以下简称兮璞材料)100%股权、浙 江贝得药业有限公司 40%股权,并募集配套资金,交易预计构成重大资产重组。 《预案》披露兮璞材料的主要盈利模式为"定制化代工+自主生产"相结合。截 3月3日，浙江向日葵大健康科技股份有限公司公告：3 月 2 日，公司及相关当事人收到浙江证监局出 具的《行政处罚事先告知书》。公司及相关责任人 ...

Core Viewpoint - The company Sunflower (300111) has terminated its acquisition of Zhanzhou Xipu Material Technology Co., Ltd. due to an investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][4]. Group 1: Acquisition Details - On September 8, 2025, the company announced a major asset restructuring plan, intending to acquire the controlling stake in Xipu Material and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [2] - The company paid a deposit of 40 million yuan to Shanghai Xipu on September 10, 2025, as part of the acquisition process [2]. - The acquisition was expected to constitute a major asset restructuring and related party transaction, but not a restructuring listing [2]. Group 2: Regulatory Concerns - On December 26, 2025, the Shenzhen Stock Exchange's ChiNext management department issued a letter of concern regarding the operational status of Xipu Material, prompting the company to verify and respond [3][4]. - The ChiNext management raised four key questions regarding Xipu Material's production capacity, financial performance, potential competition issues, and the impact of a lawsuit against its actual controller [4]. Group 3: Termination of Acquisition - On January 14, 2026, the company received a notice of investigation from the CSRC, leading to the termination of the acquisition due to non-compliance with conditions for issuing shares to purchase assets [4]. - The company announced that the termination of the acquisition would not have a significant adverse impact on its operations [4]. Group 4: Refund of Deposit - According to the agreement, if the transaction is terminated, Shanghai Xipu is required to refund the deposit within five working days [5]. - The company sent a collection letter to Shanghai Xipu on January 15, 2026, requesting the refund, and both parties agreed to explore installment repayment or other feasible arrangements [5]. Group 5: Market Performance - As of January 22, the company's stock closed at 4.68 yuan per share, reflecting a 0.86% increase, with a total market capitalization of approximately 6.024 billion yuan [6].

Core Viewpoint - The company Sunflower is under investigation by the Zhejiang Securities Regulatory Bureau for allegedly misleading statements in its restructuring plan, which has raised market concerns regarding the actual production capacity and business model of the targeted assets [1][2]. Group 1: Investigation Details - On January 14, the company received a notice from the China Securities Regulatory Commission (CSRC) regarding the formal investigation due to suspected violations of information disclosure laws [2]. - The investigation is based on the restructuring plan disclosed by the company in September 2025, which involved acquiring 100% of the shares of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of the shares of Zhejiang Beid Pharmaceutical Co., Ltd. [3]. - The CSRC's investigation aims to maintain order in the mergers and acquisitions market following the discovery of misleading statements in the restructuring proposal [1]. Group 2: Restructuring Plan and Business Model - The restructuring plan aimed to expand the company's business into the high-end semiconductor materials sector, which was expected to create a new growth curve and accelerate the transition to new productive forces [3]. - The targeted company, Xipu Materials, is involved in the research, manufacturing, and sales of high-end semiconductor materials, with products used in key processes of semiconductor manufacturing [3]. - Concerns have been raised regarding the actual production capacity of Xipu Materials' factories, which reportedly do not possess operational capabilities [5]. Group 3: Financial Performance and Market Reaction - In the first three quarters of 2025, the company reported revenue of 19.952 million yuan, a year-on-year decline of 12.09%, and a net profit attributable to shareholders of 1.3062 million yuan, down 53.10% year-on-year [7]. - Following the announcement of the investigation, the company's stock price fell by 20% to 4.96 yuan per share, resulting in a total market capitalization of 6.385 billion yuan [7].

Core Viewpoint - Zhejiang Sunflower (向日葵) is under investigation by the China Securities Regulatory Commission (CSRC) for allegedly misleading statements in its restructuring plan, which has raised market concerns regarding the actual production capacity and business model of the targeted assets [1][2]. Group 1: Investigation Details - On January 14, Zhejiang Sunflower received a notice from the CSRC regarding the formal investigation due to suspected violations of information disclosure laws [2]. - The company announced the termination of its asset restructuring plan, stating it no longer meets the conditions for issuing shares to purchase assets following the CSRC's notice [2][3]. Group 2: Business Overview - Zhejiang Sunflower focuses on the pharmaceutical sector, primarily engaged in the research, manufacturing, and sales of drugs for infections, cardiovascular diseases, and digestive systems [2]. - The restructuring plan aimed to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., intending to expand into the high-end semiconductor materials sector [3]. Group 3: Market Reaction and Financial Performance - Following the announcement of the investigation, Zhejiang Sunflower's stock price fell by 20%, closing at 4.96 yuan per share, with a total market capitalization of 6.385 billion yuan [5]. - The company's financial performance has been under pressure, with a reported revenue of 19.952 million yuan for the first three quarters of 2025, a year-on-year decline of 12.09%, and a net profit attributable to shareholders of 1.3062 million yuan, down 53.10% year-on-year [5].

Core Viewpoint - Zhejiang Sunflower (300111) is under investigation by the China Securities Regulatory Commission (CSRC) for misleading statements in its merger and acquisition (M&A) disclosure, marking the first such case in 2026 [1][2]. Group 1: Investigation and Allegations - The Zhejiang Securities Regulatory Bureau has initiated an investigation into Zhejiang Sunflower's restructuring plan due to allegations of misleading statements regarding the actual production capacity and business model of the target companies [1]. - The CSRC will handle the investigation based on comprehensive findings to maintain order in the M&A market [2]. Group 2: Proposed Transactions - Zhejiang Sunflower plans to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment, along with raising supporting funds [2]. - Xipu Material focuses on the research, development, manufacturing, and sales of high-end semiconductor materials, which are crucial in semiconductor manufacturing processes [2]. Group 3: Concerns Raised - Media reports have raised concerns that Xipu Material's factories in Zhangzhou and Lanzhou currently lack actual production capacity [3]. - The Shenzhen Stock Exchange has issued a letter of concern to Zhejiang Sunflower, requesting verification of four key issues related to the production capacity and financial performance of Xipu Material [4]. Group 4: Financial and Legal Issues - The Shenzhen Stock Exchange has requested details on Xipu Material's revenue, costs, and gross margins for 2023 and 2024, as well as information regarding its transactions with related companies [5]. - Xipu Material's actual controller, Chen Chaoqi, is involved in a commercial dispute with a lawsuit amounting to 16.8 million yuan, raising questions about potential legal obstacles to asset transfer [5]. Group 5: Company Response - As of now, Zhejiang Sunflower has not disclosed any response to the Shenzhen Stock Exchange's letter of concern [6].

Group 1 - Hendi Pharmaceutical experienced a 5% increase in stock price, reaching 13.65 CNY per share, with a trading volume of 136 million CNY and a turnover rate of 2.41%, resulting in a total market capitalization of 5.7 billion CNY [1] - Hendi Pharmaceutical, established on December 29, 1995, is located in Jingmen City, Hubei Province, and was listed on December 22, 2021. The company specializes in the research, production, and sales of chemical raw materials and formulations [1] - The main revenue composition of Hendi Pharmaceutical includes non-steroidal anti-inflammatory drugs (68.06%), cardiovascular products (16.08%), other products (8.86%), and anti-tumor drugs (6.99%) [1] Group 2 - According to data from the top ten holdings of funds, one fund under Dongfang Fund has a significant position in Hendi Pharmaceutical. The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) held 11,600 shares in the third quarter, accounting for 0.43% of the fund's net value, ranking as the sixth largest holding [2] - The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) was established on February 22, 2019, with a latest scale of 28.7844 million CNY. The fund has achieved a year-to-date return of 10.05%, ranking 895 out of 8,836 in its category, and a one-year return of 56.94%, ranking 1,801 out of 8,091 [2] - The fund manager, Wang Huaixun, has been in position for 3 years and 243 days, with the total asset scale of the fund at 799 million CNY. During his tenure, the best fund return was 70.43%, while the worst was -0.06% [2]

Group 1 - The core viewpoint of the news is that Sunflower's stock has experienced a decline in recent trading sessions, with a notable drop of 2.03% on January 7, leading to a market capitalization of 8.058 billion yuan [1] - As of January 7, the stock price is reported at 6.26 yuan per share, with a trading volume of 119 million yuan and a turnover rate of 1.45% [1] - The net outflow of main funds is 21.7157 million yuan, with significant selling pressure observed, as large orders sold 25.2535 million yuan, accounting for 21.29% of the total [1] Group 2 - Year-to-date, Sunflower's stock price has increased by 2.12%, but it has seen a decline of 2.03% over the last five trading days, 16.64% over the last 20 days, and 8.08% over the last 60 days [2] - Sunflower, established on March 21, 2005, and listed on August 27, 2010, focuses on the pharmaceutical sector, primarily in the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [2] - The company's revenue composition includes 73.44% from raw materials, 26.37% from formulated drugs, and 0.19% from other (non-main) sources [2] Group 3 - Sunflower has distributed a total of 204 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]

Group 1 - The core viewpoint of the news is that Sunflower has shown significant stock performance, with a year-to-date increase of 123.15% and a recent trading volume indicating active investor interest [1] - As of December 24, Sunflower's stock price reached 7.23 CNY per share, with a total market capitalization of 9.307 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 12.2874 million CNY, with large orders contributing significantly to the trading activity [1] Group 2 - Sunflower's main business focuses on the pharmaceutical sector, particularly in the research, production, and sales of drugs for infection, cardiovascular, and digestive system treatments [1] - The revenue composition of Sunflower includes 73.44% from raw materials, 26.37% from formulated drugs, and 0.19% from other non-main businesses [1] - As of September 30, the company reported a decrease in revenue to 200 million CNY, down 12.09% year-on-year, and a net profit of 1.3062 million CNY, down 53.10% year-on-year [2] Group 3 - Sunflower has cumulatively distributed 204 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

Group 1 - The core viewpoint of the news is that Hendi Pharmaceutical experienced a decline in stock price and trading volume, with significant changes in financing and stockholder metrics [1][2]. Group 2 - On December 23, Hendi Pharmaceutical's stock fell by 2.35%, with a trading volume of 88.08 million yuan. The financing buy-in amount was 7.56 million yuan, while the financing repayment was 6.23 million yuan, resulting in a net financing buy of 1.33 million yuan [1]. - As of December 23, the total financing and securities lending balance for Hendi Pharmaceutical was 124 million yuan, which is 2.39% of its circulating market value, indicating a low financing balance compared to the past year [1]. - In terms of securities lending, on December 23, Hendi Pharmaceutical repaid 900 shares and sold 900 shares, with a selling amount of 11,200 yuan. The remaining securities lending volume was 22,300 shares, with a balance of 277,400 yuan, which is at a high level compared to the past year [1]. Group 3 - As of December 19, the number of shareholders for Hendi Pharmaceutical was 21,400, a decrease of 3.15%, while the average circulating shares per person increased by 3.25% to 19,531 shares [2]. - For the period from January to September 2025, Hendi Pharmaceutical reported an operating income of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2]. - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2].

Group 1 - The core viewpoint of the news is that Sunflower has experienced a significant stock price fluctuation, with a year-to-date increase of 122.22% but a recent decline of 5.26% over the last five trading days [1] - As of November 19, Sunflower's stock price is 7.20 CNY per share, with a market capitalization of 9.268 billion CNY and a trading volume of 172 million CNY [1] - The company has seen a net outflow of main funds amounting to 16.5384 million CNY, with large orders showing a buy of 27.0751 million CNY and a sell of 41.7075 million CNY [1] Group 2 - Sunflower's main business focuses on the pharmaceutical sector, particularly in the research, production, and sales of drugs for anti-infection, cardiovascular, and digestive system treatments [1] - The revenue composition of Sunflower includes 73.44% from raw materials, 26.37% from formulated drugs, and 0.19% from other non-main businesses [1] - As of September 30, the number of shareholders has increased to 133,000, a rise of 112.98%, while the average circulating shares per person have decreased by 53.05% [2] Group 3 - Sunflower has distributed a total of 204 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]